WO2006049681A3 - Selective neuropeptide y2 receptor agonists - Google Patents

Selective neuropeptide y2 receptor agonists Download PDF

Info

Publication number
WO2006049681A3
WO2006049681A3 PCT/US2005/031017 US2005031017W WO2006049681A3 WO 2006049681 A3 WO2006049681 A3 WO 2006049681A3 US 2005031017 W US2005031017 W US 2005031017W WO 2006049681 A3 WO2006049681 A3 WO 2006049681A3
Authority
WO
WIPO (PCT)
Prior art keywords
receptor agonists
mammal
selective
food intake
reduce food
Prior art date
Application number
PCT/US2005/031017
Other languages
French (fr)
Other versions
WO2006049681A2 (en
Inventor
Kevin Lumb
Roger B Clark
Philip Coish
Lynn Decarr
Original Assignee
Bayer Pharmaceuticals Corp
Kevin Lumb
Roger B Clark
Philip Coish
Lynn Decarr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp, Kevin Lumb, Roger B Clark, Philip Coish, Lynn Decarr filed Critical Bayer Pharmaceuticals Corp
Publication of WO2006049681A2 publication Critical patent/WO2006049681A2/en
Publication of WO2006049681A3 publication Critical patent/WO2006049681A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57545—Neuropeptide Y

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

This invention provides peptides that act as selective NPY2 receptor agonists and may be used to reduce food intake. The invention includes a peptide selected from a specific group of derivatized NPY-related peptides, or functional equivalents thereof. The invention is also directed to a method of treating obesity or related diseases in a mammal comprising administering a therapeutically effective amount of the peptide to said mammal to reduce food intake and body weight.
PCT/US2005/031017 2004-08-30 2005-08-29 Selective neuropeptide y2 receptor agonists WO2006049681A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60608404P 2004-08-30 2004-08-30
US60/606,084 2004-08-30

Publications (2)

Publication Number Publication Date
WO2006049681A2 WO2006049681A2 (en) 2006-05-11
WO2006049681A3 true WO2006049681A3 (en) 2006-07-27

Family

ID=36319589

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/031017 WO2006049681A2 (en) 2004-08-30 2005-08-29 Selective neuropeptide y2 receptor agonists

Country Status (1)

Country Link
WO (1) WO2006049681A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5767582B2 (en) 2009-07-02 2015-08-19 武田薬品工業株式会社 Peptides and their uses
WO2011045232A2 (en) * 2009-10-13 2011-04-21 F. Hoffmann-La Roche Ag Neuropeptide-2 receptor (y-2r) agonists
SI3326620T1 (en) 2010-12-16 2020-07-31 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2- hydroxybenzoyl)amino)caprylic acid
EP4324475A1 (en) 2012-03-22 2024-02-21 Novo Nordisk A/S Compositions of glp-1 peptides and preparation thereof
MA38472B1 (en) 2013-05-28 2018-09-28 Takeda Pharmaceuticals Co Peptide compound
JP6602760B2 (en) 2013-11-15 2019-11-06 ノヴォ ノルディスク アー／エス Selective PYY compounds and uses thereof
JP6629198B2 (en) 2013-11-15 2020-01-15 ノヴォ ノルディスク アー／エス HPYY (1-36) having a β-homoarginine substitution at position 35
MA43205A (en) 2015-06-12 2018-09-19 Novo Nordisk As SELECTIVE PYY COMPOUNDS AND THEIR USES
CN105601571B (en) * 2015-12-22 2019-03-05 北京医药集团有限责任公司 Benzimidazoles derivative, preparation method and application
CN109477094B (en) 2016-05-24 2022-04-26 武田药品工业株式会社 Peptide compounds
MX2020007598A (en) 2018-02-02 2020-09-03 Novo Nordisk As Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992019254A1 (en) * 1991-04-24 1992-11-12 Warner-Lambert Company α-SUBSTITUTED POLYPEPTIDES HAVING THERAPEUTIC ACTIVITY
WO2003027637A2 (en) * 2001-09-24 2003-04-03 Oregon Health And Science University Assessment of neurons in the arcuate nucleus to screen for agents that modify feeding behavior
WO2005077072A2 (en) * 2004-02-11 2005-08-25 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992019254A1 (en) * 1991-04-24 1992-11-12 Warner-Lambert Company α-SUBSTITUTED POLYPEPTIDES HAVING THERAPEUTIC ACTIVITY
WO2003027637A2 (en) * 2001-09-24 2003-04-03 Oregon Health And Science University Assessment of neurons in the arcuate nucleus to screen for agents that modify feeding behavior
WO2005077072A2 (en) * 2004-02-11 2005-08-25 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties

Also Published As

Publication number Publication date
WO2006049681A2 (en) 2006-05-11

Similar Documents

Publication Publication Date Title
WO2006049681A3 (en) Selective neuropeptide y2 receptor agonists
WO2005120557A3 (en) Inhibition of macrophage-stimulating protein receptor (ron)
WO2006034373A3 (en) Variants and chemically-modified variants of phenylalanine ammonia-lyase
WO2006033702A3 (en) Anti-cd154 antibodies
WO2005105107A3 (en) Hormone treatment of multiple sclerosis
WO2004016750A3 (en) FcϜRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
WO2006052723A3 (en) G protein coupled receptor agonists and antagonists and methods of use
WO2005080424A3 (en) Peptide yy analogues
WO2009009562A3 (en) Glp-1-fc fusion protein formulation
WO2007147001A3 (en) Lyophilized formulations of anti-egfr antibodies
WO2006091506A3 (en) Neuropeptide y4 receptor agonists
WO2005102387A3 (en) Therapeutic use of anti-cs1 antibodies
EP2628486A3 (en) Method for treating bone fracture with anti-sclerostin antibodies
WO2005030797A3 (en) Melanocortin receptor agonists
EP2628749A3 (en) Antimicrobial kinocidin compostions and methods of use
WO2005107793A3 (en) Ngal for reduction and amelioration of ischemic and nephrotoxic injuries
WO2006023359A3 (en) Selective vpac2 receptor peptide agonists
UA99094C2 (en) Method for the treatment of patients with autoantibody positive disease
WO2008142303A3 (en) Use of an anti-cxcr4 antibody for treating cancer
WO2006057003A3 (en) Induction of neurogenesis and stem cell therapy in combination with copolymer 1
WO2006100679A3 (en) Recombinant antibodies against human type ii transglutaminase and uses thereof
WO2005072277A3 (en) Amidated parathyroid hormone fragments and uses thereof
WO2009010968A3 (en) Disease treatment via antimicrobial peptides or their inhibitors
WO2008051496A3 (en) Use of il-1 antagonists to treat gout and pseudogout
WO2006007555A3 (en) Rotavirus antigens

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase